12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Canagliflozin/metformin regulatory update

Johnson & Johnson's Janssen-Cilag International N.V. unit submitted an MAA to EMA for a fixed-dose combination of canagliflozin and immediate-release metformin to treat Type II diabetes in adult patients. Last December, J&J's Janssen Research & Development...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >